[HTML][HTML] A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo

HD Collier-Bain, A Emery, AJ Causer, FF Brown… - Brain, Behavior, and …, 2024 - Elsevier
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and
accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal …

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against autologous human chronic lymphocytic leukaemia B-cells ex vivo

HD Collier-Bain, A Emery, AJ Causer… - Brain Behavior and …, 2024 - researchportal.bath.ac.uk
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and
accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal …

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against autologous human chronic lymphocytic leukaemia B-cells ex vivo

HD Collier-Bain, A Emery, AJ Causer… - Brain, Behavior and …, 2024 - eprints.soton.ac.uk
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and
accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal …

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against autologous human chronic lymphocytic leukaemia B-cells ex vivo.

HD Collier-Bain, A Emery, AJ Causer… - Brain, Behavior, and …, 2024 - europepmc.org
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and
accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal …

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo

HD Collier-Bain, A Emery, AJ Causer… - Brain, behavior …, 2024 - pubmed.ncbi.nlm.nih.gov
Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and
accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal …